gastrointestinal neoplasms

Summary

Summary: Tumors or cancer of the GASTROINTESTINAL TRACT, from the MOUTH to the ANAL CANAL.

Top Publications

  1. ncbi Diagnosis of gastrointestinal stromal tumors: A consensus approach
    Christopher D M Fletcher
    Department of Pathology, Brigham and Women s Hospital and Harvard Medical School, Boston MA 02115, USA
    Hum Pathol 33:459-65. 2002
  2. ncbi A 5-decade analysis of 13,715 carcinoid tumors
    Irvin M Modlin
    Department of Surgery, Yale University School of Medicine, New Haven, Connecticut 06520 8062, USA
    Cancer 97:934-59. 2003
  3. ncbi Gastroenteropancreatic neuroendocrine tumours
    Irvin M Modlin
    Department of Gastroenterological Surgery, Yale University, New Haven, CT 06520 8062, USA
    Lancet Oncol 9:61-72. 2008
  4. ncbi Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
    George D Demetri
    Dana Farber Cancer Institute and Harvard Cancer Center, Boston, MA 02115, USA
    N Engl J Med 347:472-80. 2002
  5. ncbi Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors
    S Hirota
    Department of Pathology, Osaka University Medical School, Yamada oka 2 2, Suita 565, Japan
    Science 279:577-80. 1998
  6. ncbi PDGFRA activating mutations in gastrointestinal stromal tumors
    Michael C Heinrich
    Department of Medicine, Department of Pathology, Oregon Health and Science University Cancer Institute and Portland VA Medical Center, Portland, OR 97201, USA
    Science 299:708-10. 2003
  7. ncbi Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors
    Seiichi Hirota
    Department of Pathology, Osaka University Medical School, Suita, Japan
    Gastroenterology 125:660-7. 2003
  8. ncbi STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications
    D A Tuveson
    MIT Cancer Center and Department of Biology, Cambridge, MA 02139, USA
    Oncogene 20:5054-8. 2001
  9. ncbi Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor
    Michael C Heinrich
    R and D 19 3710 SW US Veterans Hospital Rd, Portland, OR 97207, USA
    J Clin Oncol 21:4342-9. 2003
  10. ncbi KIT activation is a ubiquitous feature of gastrointestinal stromal tumors
    B P Rubin
    Department of Pathology, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115, USA
    Cancer Res 61:8118-21. 2001

Detail Information

Publications286 found, 100 shown here

  1. ncbi Diagnosis of gastrointestinal stromal tumors: A consensus approach
    Christopher D M Fletcher
    Department of Pathology, Brigham and Women s Hospital and Harvard Medical School, Boston MA 02115, USA
    Hum Pathol 33:459-65. 2002
    ....
  2. ncbi A 5-decade analysis of 13,715 carcinoid tumors
    Irvin M Modlin
    Department of Surgery, Yale University School of Medicine, New Haven, Connecticut 06520 8062, USA
    Cancer 97:934-59. 2003
    ....
  3. ncbi Gastroenteropancreatic neuroendocrine tumours
    Irvin M Modlin
    Department of Gastroenterological Surgery, Yale University, New Haven, CT 06520 8062, USA
    Lancet Oncol 9:61-72. 2008
    ..Progress is unlikely to occur without development of centers of excellence, with dedicated combined clinical teams to coordinate multicentre studies, maintain clinical and tissue databases, and refine molecularly targeted therapeutics...
  4. ncbi Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
    George D Demetri
    Dana Farber Cancer Institute and Harvard Cancer Center, Boston, MA 02115, USA
    N Engl J Med 347:472-80. 2002
    ..Imatinib mesylate, a selective tyrosine kinase inhibitor, has been shown in preclinical models and preliminary clinical studies to have activity against such tumors...
  5. ncbi Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors
    S Hirota
    Department of Pathology, Osaka University Medical School, Yamada oka 2 2, Suita 565, Japan
    Science 279:577-80. 1998
    ..GISTs may originate from the interstitial cells of Cajal (ICCs) because the development of ICCs is dependent on the SCF-KIT interaction and because, like GISTs, these cells express both KIT and CD34...
  6. ncbi PDGFRA activating mutations in gastrointestinal stromal tumors
    Michael C Heinrich
    Department of Medicine, Department of Pathology, Oregon Health and Science University Cancer Institute and Portland VA Medical Center, Portland, OR 97201, USA
    Science 299:708-10. 2003
    ..Thus, KIT and PDGFRA mutations appear to be alternative and mutually exclusive oncogenic mechanisms in GISTs...
  7. ncbi Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors
    Seiichi Hirota
    Department of Pathology, Osaka University Medical School, Suita, Japan
    Gastroenterology 125:660-7. 2003
    ..We investigated the cause of GISTs without KIT mutations. Because GISTs apparently expressed platelet-derived growth factor receptor (PDGFR) alpha, we examined whether GISTs without KIT mutations had a mutation of PDGFR alpha...
  8. ncbi STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications
    D A Tuveson
    MIT Cancer Center and Department of Biology, Cambridge, MA 02139, USA
    Oncogene 20:5054-8. 2001
    ..These cell-culture-based studies support an important role for c-KIT signaling in GIST and suggest therapeutic potential for STI571 in patients afflicted by this chemoresistant tumor...
  9. ncbi Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor
    Michael C Heinrich
    R and D 19 3710 SW US Veterans Hospital Rd, Portland, OR 97207, USA
    J Clin Oncol 21:4342-9. 2003
    ..The relationship between mutations in these kinases and clinical response to imatinib was examined in a group of patients with advanced GIST...
  10. ncbi KIT activation is a ubiquitous feature of gastrointestinal stromal tumors
    B P Rubin
    Department of Pathology, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115, USA
    Cancer Res 61:8118-21. 2001
    ..These studies underscore the role of KIT activation in GIST pathogenesis, and they suggest that activated KIT might represent a universal therapeutic target in GISTs...
  11. ncbi The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors
    Isis Gayed
    Department of Nuclear Medicine, M D Anderson Cancer Center, University of Texas, Houston, Texas 77030, USA
    J Nucl Med 45:17-21. 2004
    ..Therefore, we compared the roles of (18)F-FDG PET and CT in staging and evaluation of early response to imatinib mesylate therapy in recurrent or metastatic GIST...
  12. ncbi Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial
    Jaap Verweij
    Department of Medical Oncology, Erasmus University Medical Centre, Groene Hilledijk 301, 3075 EA Rotterdam, Netherlands
    Lancet 364:1127-34. 2004
    ..Imatinib is approved worldwide for use in gastrointestinal stromal tumours (GIST). We aimed to assess dose dependency of response and progression-free survival with imatinib for metastatic GIST...
  13. ncbi Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors
    Ulrich Frank Pape
    Department of Hepatology and Gastroenterology, Chariteé Campus Virchow Clinic, Berlin University of Medicine, Berlin, Germany
    Cancer 113:256-65. 2008
    ..In 2006, a new TNM classification system was proposed for the staging and grading of upper GEP NETs...
  14. ncbi The gastroenteropancreatic neuroendocrine cell system and its tumors: the WHO classification
    Gunter Kloppel
    Department of General Pathology, University of Kiel, Kiel, Germany
    Ann N Y Acad Sci 1014:13-27. 2004
    ..On the basis of localization and of various morphological and biological criteria, we distinguish between benign neuroendocrine tumors, tumors with uncertain malignant potential, and tumors showing low-grade and high-grade malignancy...
  15. ncbi A USA registry of gastrointestinal stromal tumor patients: changes in practice over time and differences between community and academic practices
    P W T Pisters
    Department of Surgical Oncology, Sarcoma Research Center at the University of Texas MD Anderson Cancer Center, Houston, USA
    Ann Oncol 22:2523-9. 2011
    ..The objective of the study was to describe patterns of care of patients with gastrointestinal stromal tumors (GISTs) in the United States in the tyrosine kinase inhibitor (TKI) era...
  16. ncbi A guide for the diagnosis and management of gastrointestinal stromal cell tumors
    Paul S Sepe
    Beth Israel Deaconess Medical Center, Boston, MA, USA
    Nat Rev Gastroenterol Hepatol 6:363-71. 2009
    ..This Review provides a general overview of GISTs, with an emphasis on their endoscopic diagnosis, the management of localized disease, and the management of incidentally discovered GISTs...
  17. ncbi Dual roles for immunity in gastrointestinal cancers
    Cristina Ferrone
    Dana Farber Cancer Institute, 44 Binney St, Dana 520C, Boston, MA 02115, USA
    J Clin Oncol 28:4045-51. 2010
    ..Here, we discuss the dual roles of immunity in cancer development, focusing on gastrointestinal malignancies, given the depth of recent insights into the mechanisms underlying these tumors...
  18. ncbi Intratumoral heterogeneity of F-18 FDG uptake differentiates between gastrointestinal stromal tumors and abdominal malignant lymphomas on PET/CT
    Tadashi Watabe
    Department of Nuclear Medicine and Tracer Kinetics, Osaka University Graduate School of Medicine, Yamadaoka, Suita, Osaka, Japan
    Ann Nucl Med 26:222-7. 2012
    ..The purpose of this study was to evaluate the intratumoral metabolic heterogeneity of F-18 FDG uptake on PET to determine if it might be helpful to discriminate between these tumors...
  19. ncbi Surgical treatment of locally advanced, non-metastatic, gastrointestinal stromal tumours after treatment with imatinib
    R Tielen
    Department of Surgical Oncology, Radboud University Nijmegen Medical Centre, Geert Grooteplein 10, 6525 GA Nijmegen, The Netherlands
    Eur J Surg Oncol 39:150-5. 2013
    ..We report on a large cohort of locally advanced GIST patients who have been treated in four centres in the Netherlands specialized in the treatment of sarcomas...
  20. pmc Consensus report on the radiological management of patients with gastrointestinal stromal tumours (GIST): recommendations of the German GIST Imaging Working Group
    Janine Kalkmann
    Department of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, University Duisburg Essen, Hufelandstrasse 55, 45122 Essen, Germany
    Cancer Imaging 12:126-35. 2012
    ..The management of patients with GIST receiving a targeted therapy requires a standardized algorithm for imaging and an appropriate response assessment with respect to changes in lesion size and density...
  21. ncbi Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma
    J Verweij
    Department of Medical Oncology, Erasmus MC, University Medical Center Rotterdam, Groene Hilledijk 301, 3075 EA, Rotterdam, The Netherlands
    Eur J Cancer 39:2006-11. 2003
    ..Imatinib mesylate is well tolerated at a dose of 400 mg bid. This dose is active in patients with KIT-positive GIST, but patients with other STS subtypes unselected for a molecular target are unlikely to benefit...
  22. ncbi Adjuvant therapy in primary GIST: state-of-the-art
    P Reichardt
    Interdisciplinary Oncology, Helios Klinikum Berlin Buch, Berlin, Germany
    Ann Oncol 23:2776-81. 2012
    ..The objectives of this European Expert Panel meeting were to describe the optimal management and best practice for the systemic adjuvant treatment of patients with primary GISTs...
  23. ncbi Gene expression in gastrointestinal stromal tumors is distinguished by KIT genotype and anatomic site
    Cristina R Antonescu
    Departments of Pathology, Memorial Sloan Kettering Cancer Center, and Molecular Biology, Computational Biology Center, Sloan Kettering Institute, New York, New York 10021, USA
    Clin Cancer Res 10:3282-90. 2004
    ..We tested the hypothesis that the gene expression profile in GISTs might be related to KIT genotype and possibly to other clinicopathological factors...
  24. ncbi Comparison of RECIST and Choi criteria for computed tomographic response evaluation in patients with advanced gastrointestinal stromal tumor treated with sunitinib
    O Dudeck
    Department of Radiology, HELIOS Clinic Berlin Buch, Berlin, Germany
    Ann Oncol 22:1828-33. 2011
    ..Controversies exist about computed tomography (CT) response evaluation criteria for patients with gastrointestinal stromal tumor (GIST)...
  25. ncbi Comparison between 68Ga-DOTA-NOC and 18F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours
    Valentina Ambrosini
    Unità Operativa di Medicina Nucleare, Azienda Ospedaliero Universitaria di Bologna, Policlinico S Orsola Malpighi, Padiglione 30, Via Massarenti 9, 40138, Bologna, Italy
    Eur J Nucl Med Mol Imaging 35:1431-8. 2008
    ..At present, there are no comparative studies investigating their role in NET...
  26. pmc Age and alarm symptoms do not predict endoscopic findings among patients with dyspepsia: a multicentre database study
    M B Wallace
    Digestive Disease Center, Medical University of South Carolina, USA
    Gut 49:29-34. 2001
    ..Better clinical prediction strategies are needed to identify patients with significant upper gastrointestinal pathology...
  27. ncbi Occurrence of gastrointestinal cancer in users of bisphosphonates and other antiresorptive drugs against osteoporosis
    Peter Vestergaard
    The Osteoporosis Clinic, Department of Endocrinology and Internal Medicine MEA, Aarhus University Hospital THG, Denmark
    Calcif Tissue Int 89:434-41. 2011
    ..However, the association may not be causal as no dose-response or time relationship was present. For colon cancer, the decline with increasing alendronate dose may be due to a "healthy user" effect...
  28. ncbi Gastroenteropancreatic neuroendocrine tumours: the current incidence and staging based on the WHO and European Neuroendocrine Tumour Society classification: an analysis based on prospectively collected parameters
    Martin B Niederle
    Division of General Surgery, Department of Surgery, Medical University of Vienna, Vienna, Austria
    Endocr Relat Cancer 17:909-18. 2010
    ..7%) were grade 1, 31.2% grade 2 and 9.1% grade 3. NETs of the digestive tract are more common than previously reported; the majority show benign behaviour, are located in the stomach and are well differentiated. G3 tumours are very rare...
  29. ncbi Prognostic factors influencing survival from metastatic (stage IV) gastroenteropancreatic well-differentiated endocrine carcinoma
    Cosimo Durante
    Service de Médecine Nucléaire et de Cancérologie Endocrinienne, Institut Gustave Roussy, Universite Paris XI, 94805 Villejuif Cedex, France
    Endocr Relat Cancer 16:585-97. 2009
    ..This study enables the stratification of metastatic GEP WDEC patients into distinct risk groups. These risk categories can be used to tailor therapeutic approaches and also to design and interpret clinical trials...
  30. ncbi Survival and prognostic factor analysis of 146 metastatic neuroendocrine tumors of the mid-gut
    Jonathan Strosberg
    H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33629, USA
    Neuroendocrinology 89:471-6. 2009
    ..Past analyses of survival suggest a trend towards improving longevity among patients with metastatic mid-gut NETs...
  31. pmc Association between H-RAS T81C genetic polymorphism and gastrointestinal cancer risk: a population based case-control study in China
    Yongjing Zhang
    Department of Epidemiology and Health Statistics, Zhejiang University School of Medicine, Hangzhou 310058, Zhejiang, PR China
    BMC Cancer 8:256. 2008
    ..Therefore, we hypothesized that this polymorphisms in H-RAS could influence susceptibility to gastrointestinal cancer as well, and we conducted this study to test the hypothesis in Chinese population...
  32. ncbi The use of Cytokeratin 19 (CK19) immunohistochemistry in lesions of the pancreas, gastrointestinal tract, and liver
    Richa Jain
    Department of Pathology, The Toronto General Hospital, University Health Network University of Toronto, Toronto, Ontario, Canada
    Appl Immunohistochem Mol Morphol 18:9-15. 2010
    ..It can also be used to highlight native ductules in the liver and helps separate conditions such as focal nodular hyperplasia from hepatic adenoma. The vast majority of adenocarcinomas in the GIT and pancreas are CK19 positive...
  33. pmc State reduction for network intervention in probabilistic Boolean networks
    Xiaoning Qian
    Department of Computer Science and Engineering, University of South Florida, Tampa, FL 33620, USA
    Bioinformatics 26:3098-104. 2010
    ..A major obstacle for its application is the large state space of the underlying Markov chain, which poses a serious computational challenge. Hence, it is critical to reduce the model complexity of PBNs for practical applications...
  34. ncbi Primary gastrointestinal lymphoma in Japan: a clinicopathologic analysis of 455 patients with special reference to its time trends
    Shotaro Nakamura
    Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
    Cancer 97:2462-73. 2003
    ..This study aimed to elucidate the clinicopathologic features of this disease and the influence of therapeutic modalities on the prognosis in Japanese patients..
  35. ncbi GeneChip, geNorm, and gastrointestinal tumors: novel reference genes for real-time PCR
    Mark Kidd
    Gastrointestinal Research Group, Yale University School of Medicine, New Haven, Connecticut, USA
    Physiol Genomics 30:363-70. 2007
    ....
  36. ncbi Development of a disease-specific Quality of Life questionnaire module for patients with gastrointestinal neuroendocrine tumours
    A H G Davies
    Institute of Liver Studies, Carcinoid Clinic, King s College Hospital, Denmark Hill, London SE5 9RS, UK
    Eur J Cancer 42:477-84. 2006
    ..The EORTC QLQ-NET21 provides a site-specific module to supplement the QLQ-C30 for patients with neuroendocrine tumours...
  37. ncbi Gastrointestinal stromal tumours (GISTs) negative for KIT (CD117 antigen) immunoreactivity
    Maria Debiec-Rychter
    Laboratory for Cytogenetics and Molecular Genetics of Human Malignancies, Department of Human Genetics, Catholic University of Leuven, Belgium
    J Pathol 202:430-8. 2004
    ..While intragenic PDGFRA activating mutations are present in some of these tumours, the oncogenic events underlying the pathogenesis of the others remain unknown...
  38. ncbi Pathogenesis of adenocarcinoma in Peutz-Jeghers syndrome
    S B Gruber
    Division of Molecular Medicine and Genetics, University of Michigan, Ann Arbor 48109, USA
    Cancer Res 58:5267-70. 1998
    ..Additional somatic mutational events underlie the progression of hamartomas to adenocarcinomas, and some of these somatic mutations are common to the later stages of tumor progression seen in the majority of colorectal carcinomas...
  39. ncbi Computed tomography in gastrointestinal stromal tumors
    Nadir Ghanem
    Department of Diagnostic Radiology, University Hospital Freiburg, Hugstetter Strasse 55, 79106 Freiburg, Germany
    Eur Radiol 13:1669-78. 2003
    ....
  40. pmc Inflammasomes in intestinal inflammation and cancer
    Grace Y Chen
    Division of Hematology and Oncology, Department of Internal Medicine, and Comprehensive Cancer Center, University of Michigan, Ann Arbor, Michigan 48109, USA
    Gastroenterology 141:1986-99. 2011
    ....
  41. ncbi Perioperative immunonutrition for gastrointestinal cancer: a systematic review of randomized controlled trials
    Yan Zhang
    Gansu Provincial Hospital, Donggang West Road No 204, Chengguan District, Lanzhou City, Gansu Province, China
    Surg Oncol 21:e87-95. 2012
    ..To improve the clinical outcome, immunonutrition (IN) was usually used in the patients undergoing elective gastrointestinal caner surgery. However, its effectiveness remains uncertain...
  42. ncbi Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. A consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS)
    U Plockinger
    Department of Hepatology and Gastroenterology, Interdisciplinary Center for Metabolism, Endocrinology, and Diabetes, Charite Universitatsmedizin Berlin, Campus Virchow Klinikum, Berlin, Germany
    Neuroendocrinology 80:394-424. 2004
  43. ncbi Gastrointestinal stromal tumors--definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis
    M Miettinen
    Department of Soft Tissue Pathology, Armed Forces Institute of Pathology, Washington, DC 20306 6000, USA
    Virchows Arch 438:1-12. 2001
    ..Angiosarcomas and metastatic melanomas, both of which are often KIT-positive, should not be confused with GISTs...
  44. ncbi Hepatic surgery for metastases from neuroendocrine tumors
    Juan M Sarmiento
    Division of Gastroenterologic and General Surgery, Mayo Clinic, Mayo Foundation, 200 First Street SW, Rochester, MN 55905, USA
    Surg Oncol Clin N Am 12:231-42. 2003
    ..The best hope physicians can offer these patients is an extended survival period with minimal endocrine symptoms and decreased requirements of somatostatin analogs...
  45. ncbi Malignant gastrointestinal stromal tumor: distribution, imaging features, and pattern of metastatic spread
    Guy J C Burkill
    Department of Radiology, Royal Marsden Hospital, Fulham Rd, London SW3 6JJ, England
    Radiology 226:527-32. 2003
    ..To investigate and describe the anatomic distribution, imaging features, and pattern of metastatic spread of malignant gastrointestinal stromal tumors (GISTs)...
  46. pmc Small-cell carcinoma of the gastrointestinal tract: a retrospective study of 64 cases
    B Brenner
    The Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Br J Cancer 90:1720-6. 2004
    ..Mixed tumour histology is common and may affect therapy. Surgery, combined with chemotherapy, should be considered for LD. The value of the VALSG system was implied and possible differences from small-cell lung cancer were noted...
  47. pmc Genetic variation in the prostate stem cell antigen gene and upper gastrointestinal cancer in white individuals
    Paul Lochhead
    Gastrointestinal Research Group, Institute of Medical Sciences, University of Aberdeen, Aberdeen, Scotland
    Gastroenterology 140:435-41. 2011
    ..We set out to determine whether such an association exists in white individuals...
  48. ncbi Association of KIT exon 9 mutations with nongastric primary site and aggressive behavior: KIT mutation analysis and clinical correlates of 120 gastrointestinal stromal tumors
    Cristina R Antonescu
    Department of Pathology, Memorial Sloan Kettering Cancer Center, and Molecular Biology Program, Sloan Kettering Institute, New York, New York, 10021, USA
    Clin Cancer Res 9:3329-37. 2003
    ..The impact of KIT mutation in other regions, such as the extracellular or kinase domains, is not well-defined and fewer than 30 cases have been published to date...
  49. pmc KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size
    Christopher L Corless
    Department of Pathology, Division of Hematology Oncology, Oregon Health and Science University, Portland, 97201, USA
    Am J Pathol 160:1567-72. 2002
    ..The findings suggest that KIT mutations per se are of little prognostic importance in GISTs...
  50. pmc Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects
    Christophe Borg
    Department of Clinical Biology, Equipe de Recherche Mixte 0208, INSERM, Institut Gustave Roussy, Villejuif, France
    J Clin Invest 114:379-88. 2004
    ..These data point to a novel mode of antitumor action for Gleevec...
  51. ncbi Surgery and radiofrequency ablation for treatment of liver metastases from midgut and foregut carcinoids and endocrine pancreatic tumors
    John Eriksson
    Department of Surgery, University Hospital, SE 751 85 Uppsala, Sweden
    World J Surg 32:930-8. 2008
    ..However, it is not clear whether such therapy will provide symptom reduction or increased survival...
  52. ncbi PKC theta, a novel immunohistochemical marker for gastrointestinal stromal tumors (GIST), especially useful for identifying KIT-negative tumors
    Atsushi Motegi
    Department of Tumor Pathology, Graduate School of Medicine, Gunma University, Maebashi shi, Gunma, Japan
    Pathol Int 55:106-12. 2005
    ..The present study revealed that PKC theta is an immunohistochemically novel and useful marker for GIST, especially for GIST negative for KIT...
  53. ncbi Surgery as primary treatment in patients with liver metastases from carcinoid tumors: a retrospective, unicentric study over 13 years
    H Nave
    Clinic of Visceral and Transplantation Surgery, Hannover Medical School, Hannover, Germany
    Surgery 129:170-5. 2001
    ..CONCLUSIONS: Surgery for metastatic carcinoid tumors may be curative or palliative, with a potential for cure in some cases and prolongation of survival and amelioration of symptoms in the majority of patients...
  54. ncbi Application of C12 multi-tumor marker protein chip in the diagnosis of gastrointestinal cancer: results of 329 surgical patients and suggestions for improvement
    Xue Qin Yang
    Department of Oncology, Zhongnan Hospital of Wuhan University, Hubei Cancer Clinical Study Center and Hubei Key Laboratory on Tumor Biological Behaviors, Wuhan, 430071, China
    Hepatogastroenterology 56:1388-94. 2009
    ..Serum tumor markers (TMs) are frequently used in the diagnosis of GI cancer. This study was to assess value of C12 multi-tumor marker protein chip diagnostic system developed in China in GI cancer...
  55. ncbi A prospective study comparing endoscopy and EUS in the evaluation of GI subepithelial masses
    Joo Ha Hwang
    Department of Medicine, Division of Gastroenterology, University of Washington, Seattle, 98195, USA
    Gastrointest Endosc 62:202-8. 2005
    ..The purpose of this study is to prospectively evaluate the performance characteristics of endoscopy and EUS in the diagnosis of GI subepithelial masses...
  56. ncbi Gastrointestinal stromal tumors: biology and treatment
    Florence Duffaud
    Service d Oncologie Medicale, CHU Timone Adultes, Marseille, France
    Oncology 65:187-97. 2003
    ..Additional follow-up is necessary. Glivec treatment of GIST is the first example of an efficient targeted treatment in a solid tumor...
  57. ncbi A two-arm phase II study of temozolomide in patients with advanced gastrointestinal stromal tumors and other soft tissue sarcomas
    Jonathan C Trent
    Department of Sarcoma Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 98:2693-9. 2003
    ..Patients with GIST were eligible regardless of prior therapy before imatinib was available...
  58. ncbi Clinical utility of the new American Joint Committee on Cancer staging system for gastrointestinal stromal tumors: current overall survival after primary tumor resection
    Piotr Rutkowski
    Department of Soft Tissue Bone Sarcoma and Melanoma, Maria Sklodowska Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland
    Cancer 117:4916-24. 2011
    ....
  59. ncbi Gastrointestinal stromal tumors (GISTs): definition, occurrence, pathology, differential diagnosis and molecular genetics
    Markku Miettinen
    Department of Soft Tissue Pathology, Armed Forces Institute of Pathology, Washington, DC 20306 6000, USA
    Pol J Pathol 54:3-24. 2003
    ..Majority of these mutations are in-frame-deletions and missense mutations clustering in the 5'-end of juxtamembrane domain (exon 11). A rare mutation, an Ala502-Tyr503 duplication in exon 9, is specific for intestinal GISTs...
  60. ncbi Gastrointestinal stromal tumors (GISTs) with KIT and PDGFRA mutations have distinct gene expression profiles
    Subbaya Subramanian
    Department of Pathology, Stanford University Medical Center, Stanford, CA 94305, USA
    Oncogene 23:7780-90. 2004
    ..These gene products could serve as highly selective therapeutic targets in GISTs containing the KIT or PDGFRA mutational types with which they are associated...
  61. pmc Patterns of deregulation of insulin growth factor signalling pathway in paediatric and adult gastrointestinal stromal tumours
    Antoine Italiano
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Eur J Cancer 48:3215-22. 2012
    ..Data regarding the patterns and the mechanisms of deregulation of the insulin growth factor (IGF) pathway in adult and paediatric gastrointestinal stromal tumours (GISTs) are limited...
  62. ncbi Attempted endoscopic en bloc resection of mucosal and submucosal tumors using insulated-tip knives: a pilot series
    T Rosch
    Department of Internal Medicine II and Pathology, Technical University of Munich, Munich, Germany
    Endoscopy 36:788-801. 2004
    ....
  63. pmc Lack of association of miR-146a rs2910164 polymorphism with gastrointestinal cancers: evidence from 10206 subjects
    Fang Wang
    Department of Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
    PLoS ONE 7:e39623. 2012
    ..Accordingly, we conducted a comprehensive literature search and a meta-analysis to clarify the association...
  64. ncbi Chromogranin A is a reliable biomarker for gastroenteropancreatic neuroendocrine tumors in an Asian population of patients
    Wen Chi Chou
    Division of Hematology Oncology, Chang Gung Memorial Hospital at Linkou, Chang Gung University College of Medicine, No 5 Fushing St, Kweishan Shiang, Taoyuan, Taiwan, ROC
    Neuroendocrinology 95:344-50. 2012
    ..To evaluate the significance of plasma chromogranin A (CgA) levels in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NET) in terms of disease status and treatment responses...
  65. ncbi IL-18 serum level and IL-18 promoter gene polymorphism in Iranian patients with gastrointestinal cancers
    Mohammad Reza Haghshenas
    Shiraz Institute for Cancer Research, Shiraz University of Medical Sciences, Shiraz, Iran
    J Gastroenterol Hepatol 24:1119-22. 2009
    ..Interleukin (IL)-18 level and association of its two promoter gene polymorphisms at -607 C/A and -137 G/C positions were investigated in Iranian patients with gastrointestinal (GI) cancers...
  66. ncbi Aberrant DNA methylation associated with aggressiveness of gastrointestinal stromal tumour
    Yasuyuki Okamoto
    Division of Molecular Oncology, Aichi Cancer Center Research Institute, 1 1 Kanokoden, Chikusa ku, Nagoya 464 8681, Japan
    Gut 61:392-401. 2012
    ..Our aim was to establish epigenetic profiles associated with the malignant transformation of GISTs...
  67. ncbi The diagnosis and medical management of advanced neuroendocrine tumors
    Gregory A Kaltsas
    Department of Endocrinology, St Bartholomew s Hospital, London EC1A 7BE, United Kingdom
    Endocr Rev 25:458-511. 2004
    ..Maintenance of the quality of life should be a priority, particularly because patients with disseminated disease may experience prolonged survival...
  68. ncbi Impact of endoscopic ultrasound for evaluation of submucosal lesions in gastrointestinal tract
    B Brand
    Department of Interdisciplinary Endoscopy, University Hospital Eppendorf, Hamburg, Germany
    Dig Liver Dis 34:290-7. 2002
    ..Endoscopic ultrasound is widely used following endoscopy for evaluation of suspected submucosal lesions and may guide further management of patients...
  69. ncbi Polymorphism of thymidylate synthase gene and chemosensitivity of 5-fluorouracil regimen in metastatic gastrointestinal cancer
    Yue Hong Cui
    Department of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, China
    J Dig Dis 10:118-23. 2009
    ..To explore the polymorphism of thymidylate synthase (TS) gene and chemosensitivity of a 5-fluorouracil (5-FU)-containing regimen in metastatic colorectal and gastric cancer...
  70. ncbi Therapeutic options for gastrointestinal carcinoids
    Irvin M Modlin
    Department of Surgery, Yale University School of Medicine, New Haven, Connecticut 06520 8062, USA
    Clin Gastroenterol Hepatol 4:526-47. 2006
    ..The keystone of current therapy remains the long-acting somatostatin analogues that alleviate symptomatology and substantially improve quality of life with minimal adverse effects...
  71. ncbi NF1-associated gastrointestinal stromal tumors have unique clinical, phenotypic, and genotypic characteristics
    Johanna Andersson
    Lundberg Laboratory for Cancer Research, Department of Pathology, Sahlgrenska Academy, Goteborg University, Goteborg, Sweden
    Am J Surg Pathol 29:1170-6. 2005
    ..NF1-associated GIST are also phenotypically and genotypically distinct from sporadic GIST, indicating that different pathogenetic mechanisms are involved in their evolution...
  72. ncbi Primary gastrointestinal non-Hodgkin's lymphoma: a clinicopathologic study of 128 cases in Greece. A Hellenic Cooperative Oncology Group study (HeCOG)
    George Papaxoinis
    Second Department of Internal Medicine, Athens University, University General Hospital Attikon, Haidari, Greece
    Leuk Lymphoma 47:2140-6. 2006
    ..0001). The International Prognostic Index (IPI) for patients with aggressive lymphomas was prognostic only for DFS (79% for low-risk patients [IPI score 0 - 1] vs 49% for higher risk groups [IPI score >1] at 3-year, P = 0.0131)...
  73. ncbi Cruciferous vegetables, mushrooms, and gastrointestinal cancer risks in a multicenter, hospital-based case-control study in Japan
    Megumi Hara
    Epidemiology and Biostatistics Division, National Cancer Center Research Institute East, Chiba, Japan
    Nutr Cancer 46:138-47. 2003
    ..These findings suggest that cruciferous vegetables decrease the risk of both stomach and colorectal cancer, and that mushrooms are associated with a decreased risk of stomach cancer...
  74. ncbi Systematic review: primary and secondary prevention of gastrointestinal cancers with antioxidant supplements
    G Bjelakovic
    The Cochrane Hepato Biliary Group, Copenhagen Trial Unit, Centre for Clinical Intervention Research, Rigs Hospitalet, Copenhagen University Hospital, Copenhagen, Denmark
    Aliment Pharmacol Ther 28:689-703. 2008
    ..The evidence on whether antioxidant supplements prevent gastrointestinal cancers is contradictory...
  75. pmc Development of Cryptosporidium parvum-induced gastrointestinal neoplasia in severe combined immunodeficiency (SCID) mice: severity of lesions is correlated with infection intensity
    Gabriela Certad
    Ecologie du Parasitisme EA3609 Université de Lille 2, IFR 142, Institut Pasteur de Lille, Lille, France
    Am J Trop Med Hyg 82:257-65. 2010
    ..Immunohistochemistry for Ki-67 staining indicated the neoplastic process associated to cryptosporidiosis, and evidenced the first immunohistochemical alterations at early stages of the process, even at 3 weeks PI...
  76. ncbi Gastrointestinal stromal tumors (GIST): C-kit mutations, CD117 expression, differential diagnosis and targeted cancer therapy with Imatinib
    Chandu M V de Silva
    University Department of Pathology, Western Infirmary, Glasgow, G11 6NT, UK
    Pathol Oncol Res 9:13-9. 2003
    ..This review summarises recent advances in knowledge regarding the histogenesis, pathology, molecular biology, genetics and differential diagnosis of GISTs and the basis for the novel targeted cancer therapy with imatinib...
  77. ncbi Impact of chromogranin A measurement in the work-up of neuroendocrine tumors
    E Baudin
    Department of Nuclear Medicine and Endocrine Tumors, Institut Gustave Roussy, Villejuif, France
    Ann Oncol 12:S79-82. 2001
    ..Both tumor burden and secretory activity should be taken into account when interpreting CgA results...
  78. ncbi Immunohistochemical staining for CDX-2, PDX-1, NESP-55, and TTF-1 can help distinguish gastrointestinal carcinoid tumors from pancreatic endocrine and pulmonary carcinoid tumors
    Amitabh Srivastava
    Dartmouth Medical School, Dartmouth Hitchcock Medical Center Lebanon, NH, USA
    Am J Surg Pathol 33:626-32. 2009
    ..TTF-1 positivity was confined to pulmonary carcinoids in our study but was present in only about a third of cases. A panel of these 4 markers may be useful in predicting the primary site of metastatic WDNET...
  79. pmc A functional NQO1 609C>T polymorphism and risk of gastrointestinal cancers: a meta-analysis
    Hongping Yu
    Department of Epidemiology, The University of Texas, M D Anderson Cancer Center, Houston, Texas, United States of America
    PLoS ONE 7:e30566. 2012
    ....
  80. ncbi A single-institution experience with concurrent capecitabine and radiation therapy in gastrointestinal malignancies
    U N Vaishampayan
    Department of Internal Medicine, Division of Oncology, The Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI, USA
    Int J Radiat Oncol Biol Phys 53:675-9. 2002
    ..We report our clinical experience with 32 patients receiving concurrent irradiation and capecitabine...
  81. ncbi Beta-catenin immunohistochemistry separates mesenteric fibromatosis from gastrointestinal stromal tumor and sclerosing mesenteritis
    Elizabeth Montgomery
    Department of Pathology, Johns Hopkins School of Medicine, Baltimore, Maryland 21205, USA
    Am J Surg Pathol 26:1296-301. 2002
    ..beta-Catenin staining identifies lesions that are, instead, mesenteric fibromatoses...
  82. ncbi Plasma chromogranin a in patients with inflammatory bowel disease
    Valentina Sciola
    Gastroenterology Unit II, Fondazione IRCCS Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena, University of Milan, Milan, Italy
    Inflamm Bowel Dis 15:867-71. 2009
    ..Therefore, we aimed to evaluate CgA levels and their possible relationship with clinical and biochemical disease activity indexes in 119 IBD patients...
  83. ncbi Alarm features and age for predicting upper gastrointestinal malignancy in Chinese patients with dyspepsia with high background prevalence of Helicobacter pylori infection and upper gastrointestinal malignancy: an endoscopic database review of 102,665 pat
    Yu Bai
    Department of Gastroenterology, Changhai Hospital, Second Military Medical University, 168 Changhai Road, Shanghai, China
    Gut 59:722-8. 2010
    ..The aim of the present study was to determine the diagnostic accuracy of alarm features in predicting upper GI malignancy by reviewing an endoscopic database consisting of >100,000 Chinese patients...
  84. ncbi Primary follicular lymphoma of the gastrointestinal tract: a study of 25 cases and a literature review
    G Damaj
    Hopital Necker Enfants Malades, Paris, France
    Ann Oncol 14:623-9. 2003
    ..To describe better the clinical, biological, endoscopic and pathological presentations, as well as the outcome, of primary follicular lymphoma (FL) of the gastrointestinal (GI) tract...
  85. ncbi Proliferation of antigen MIB-1 in metastatic carcinoid tumours removed at liver transplantation: relevance to prognosis
    Anjali D Amarapurkar
    Institute of Liver Studies and Carcinoid Clinic, King s College Hospital, Denmark Hill, London SE5 9RS, UK
    Eur J Gastroenterol Hepatol 15:139-43. 2003
    ..The MIB-1 antibody, which detects cell proliferative activity, has been shown to be a useful prognostic marker for a variety of neoplasms...
  86. ncbi Meta-analysis: the diagnostic value of alarm symptoms for upper gastrointestinal malignancy
    G A J Fransen
    Department of General Practice, Maastricht University, Maastricht, The Netherlands
    Aliment Pharmacol Ther 20:1045-52. 2004
    ..Usually alarming symptoms are used for this matter, but their diagnostic value is by no means clear...
  87. ncbi Repeatability of 18F-FDG PET in a multicenter phase I study of patients with advanced gastrointestinal malignancies
    Linda M Velasquez
    Bristol Myers Squibb Co, Princeton, New Jersey 08543, USA
    J Nucl Med 50:1646-54. 2009
    ....
  88. ncbi European Organisation of Research and Treatment of Cancer (EORTC) Gastrointestinal Group: Workshop on the role of metabolic imaging in the neoadjuvant treatment of gastrointestinal cancer
    Florian Lordick
    National Centre for Tumour Diseases, Department of Medical Oncology, University of Heidelberg, Im Neuenheimer Feld 350, 69120 Heidelberg, Germany
    Eur J Cancer 44:1807-19. 2008
    ..This paper reviews the lectures and discussions held during this workshop and summarises the action points for the further investigation of metabolic imaging to guide treatment in gastrointestinal tumours...
  89. ncbi Occupational exposure to hexavalent chromium and cancers of the gastrointestinal tract: a meta-analysis
    Nicole M Gatto
    ToxStrategies, Inc, Rancho Santa Margarita, CA, USA
    Cancer Epidemiol 34:388-99. 2010
    ..We conducted a systematic literature review and meta-analysis of oral cavity, esophageal, stomach, small intestine, colon, and rectal cancers among workers occupationally exposed to Cr(VI)...
  90. pmc Descriptive epidemiology of gastrointestinal non-Hodgkin's lymphoma in a population-based registry
    K A Gurney
    Leukaemia Research Fund Centre for Clinical Epidemiology, University of Leeds, UK
    Br J Cancer 79:1929-34. 1999
    ..Overall, the incidence of gastrointestinal NHL significantly increased by 2.7% per annum and was limited to the population aged over 50 years in this series...
  91. ncbi Somatostatin receptor imaging for neuroendocrine tumors
    Wouter W de Herder
    Department of Internal Medicine, Section of Endocrinology, Erasmus MC, Rotterdam, The Netherlands
    Pituitary 9:243-8. 2006
    ..However, a large variety of lesions in and around the pituitary region also express somatostatin receptors and, therefore, can be visualized by (111)In-pentetreotide scintigraphy...
  92. ncbi Surgical treatment of patients with initially inoperable and/or metastatic gastrointestinal stromal tumors (GIST) during therapy with imatinib mesylate
    Piotr Rutkowski
    Department of Soft Tissue Bone Sarcoma and Melanoma, M Sklodowska Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland
    J Surg Oncol 93:304-11. 2006
    ..The aim of the study was to analyze the surgical possibilities of unresectable and/or metastatic GIST CD117(+) patients during imatinib treatment...
  93. ncbi Prognostic significance of c-kit mutation in localized gastrointestinal stromal tumors
    Tae Won Kim
    Section of Oncology Hematology, Department of Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea
    Clin Cancer Res 10:3076-81. 2004
    ..Constitutive mutational activation of c-kit has been found to be associated with the pathogenesis of gastrointestinal stromal tumors (GISTs). The prognostic significance of c-kit mutations, however, is still controversial...
  94. ncbi Chromogranin A as a marker of neuroendocrine neoplasia: an Italian Multicenter Study
    Maria Chiara Zatelli
    Section of Endocrinology, Department of Biomedical Sciences and Advanced Therapies, University of Ferrara, Via Savonarola 9, 44100 Ferrara, Italy
    Endocr Relat Cancer 14:473-82. 2007
    ....
  95. ncbi The prevalence of clinically significant endoscopic findings in primary care patients with uninvestigated dyspepsia: the Canadian Adult Dyspepsia Empiric Treatment - Prompt Endoscopy (CADET-PE) study
    A B R Thomson
    University of Alberta, Edmonton, Alberta, Canada
    Aliment Pharmacol Ther 17:1481-91. 2003
    ..Uninvestigated dyspepsia is common in family practice. The prevalence of clinically significant upper gastrointestinal findings (CSFs) in adult uninvestigated dyspepsia patients, and their predictability based on history, is unknown...
  96. ncbi Gastrointestinal stromal tumours
    M Miettinen
    Department of Soft Tissue Pathology, Armed Forces Institute of Pathology, Washington, DC, USA
    Ann Chir Gynaecol 87:278-81. 1998
    ....
  97. ncbi Efficacy and safety of prolonged-release lanreotide in patients with gastrointestinal neuroendocrine tumors and hormone-related symptoms
    A N Wymenga
    Department of Medical Oncology, University Hospital, Groningen, The Netherlands
    J Clin Oncol 17:1111. 1999
    ....
  98. ncbi Early-stage carcinoids of the gastrointestinal tract: an analysis of 1914 reported cases
    Jun Soga
    Niigata Seiryo University, Niigata, Japan
    Cancer 103:1587-95. 2005
    ..1-10.0 mm) tumors at a depth of invasion restricted to the mucosa and submucosa (sm carcinoids)...
  99. ncbi Mechanism of increased lipolysis in cancer cachexia
    Thorhallur Agustsson
    Department of Surgery, Karolinska Institutet at Karolinska University Hospital, Stockhom, Sweden
    Cancer Res 67:5531-7. 2007
    ..The selective inhibition of this enzyme may prevent fat loss in cancer patients...
  100. ncbi Defining molecular classifications and targets in gastroenteropancreatic neuroendocrine tumors through DNA microarray analysis
    Eva Maria Duerr
    Gastrointestinal Unit, Department of Medicine, Cancer Center, Center for Computational and Integrative Biology, Massachusetts General Hospital, Boston, MA 02114, USA
    Endocr Relat Cancer 15:243-56. 2008
    ..This suggests that molecular profiling may enhance tumor classification schemes. Potential gene targets have also been identified, and PDGFR and RET are candidates that may represent novel therapeutic targets...
  101. ncbi Primary gastrointestinal non-Hodgkin's lymphoma. A population based study in central Finland in 1975-1993
    L Halme
    Fourth Department of Surgery, Helsinki University Hospital, Finland
    Acta Oncol 36:69-74. 1997
    ..In conclusion the early distinction of gastrointestinal lymphomas is vital because of an increasing frequency of predisposing factors and a better prognosis due to new combination therapies...

Research Grants66

  1. Molecular Strategies for Gastric Carcinoid Surgery
    Irvin Modlin; Fiscal Year: 2005
    ..A pre-operative determination of the neoplastic ECL cell gene expression relating to gastrin responsiveness will improve the rationale for therapeutic gastric or antral resection. ..
  2. TITLE OMMITTED
    Kenneth Wang; Fiscal Year: 2001
    ..Endoscopic biopsies are routinely obtained from gastrointestinal neoplasms but two major problems have prevented their utilization for molecular analysis...
  3. Partner-Assisted Emotional Disclosure for GI Cancer
    Laura Porter; Fiscal Year: 2006
    ..If successful, it may enlarge our repertoire of methods for effectively increasing social support and enhancing the well being of both cancer patients and their partners. ..
  4. Dectection of occult mediastinal lymph node mestastases
    Michael Wallace; Fiscal Year: 2007
    ..In the R33 component of the grant application these criteria will be prospectively evaluated and correlated with clinical outcome in a second, larger cohort of patients. ..
  5. Randomized Trial of EUS Neurolysis in Pancreas Cancer
    Michael Wallace; Fiscal Year: 2006
    ..The primary outcome will be a reduction in pain at 1 month. Secondary outcomes will include the durability of pain control, quality of life, narcotic use and narcotic side effects. [unreadable] [unreadable]..
  6. Natural Killer Dendritic Cells in Listeria Infection
    Ronald DeMatteo; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  7. Palliative Oxygen for the Relief of Breathlessness
    Amy Abernethy; Fiscal Year: 2007
    ..The results will also advance a long-standing international debate about the role of palliative oxygen for intractable dyspnea and it's funding. [unreadable] [unreadable] [unreadable]..
  8. Creation and demonstration of a palliative care research cooperative group
    Jean S Kutner; Fiscal Year: 2010
    ....
  9. International Symposium on Cancer Metastasis and the Lymphovascular System
    STANLEY LEONG; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable] [unreadable]..
  10. Molecular strategies to define carcinoids and rationalize surgical intervention
    Irvin Modlin; Fiscal Year: 2009
    ..This will provide novel biological information and provide molecular data to identify occult metastasis predict spread and facilitate preemptive appropriate therapy. ..
  11. STI571 Therapy for Gastrointestinal Stromal Tumors
    Ronald DeMatteo; Fiscal Year: 2002
    ..The results are essential to advance our understanding of GIST biology and determine the therapeutic value and limitations of STI571. ..
  12. Enhanced Smoking Cessation for University Students
    Alexander V Prokhorov; Fiscal Year: 2010
    ..It will set the stage for a randomized, controlled trial of the smoking prevention and cessation methods among this high-risk population. ..
  13. Novel Signaling Targets in GI Neuroendocrine Tumors
    Herbert Chen; Fiscal Year: 2005
    ..The possibility that raf-l-mediated hormone suppression could be induced by a soluble factor would provide a plausible, therapeutic delivery method. ..
  14. Epidemiology of Syndromic GI Stromal Tumors
    Judy Ellen Garber; Fiscal Year: 2010
    ..Our goal is to define the spectrum of syndromic GISTs, and to generate the information that will form the basis for clinical counseling for members of GIST kindreds, with and without germline mutations in KIT or PDGFRA. ..
  15. Antitumor Activity of Inducible Nitric Oxide Synthase
    Keping Xie; Fiscal Year: 2005
    ..Collectively, all of these insightful studies will be crucial to effectively targeting the iNOS/NO pathway in designing novel therapeutic strategies or improving current therapeutic modalities against cancer. ..
  16. PHENOTYPIC AND PSYCHOSOCIAL STUDY OF THE L1307K MUTATION
    Henry Lynch; Fiscal Year: 2004
    ....
  17. Metal Carcinogenesis: New Concepts
    Anatoly Zhitkovich; Fiscal Year: 2006
    ..unreadable] [unreadable] [unreadable] [unreadable]..
  18. Endothelial Nitric Oxide Synthase & Portal Hypertension
    Vijay Shah; Fiscal Year: 2002
    ..abstract_text> ..
  19. Structure, Process and Outcomes in Cancer Surgery
    John D Birkmeyer; Fiscal Year: 2010
    ..We will then identify the resources and processes of care that account for differences in hospital outcomes, with the ultimate goal of identifying best practices and improving care in all settings. ..
  20. Geographic Variation of Breast Cancer Survival
    Mario Schootman; Fiscal Year: 2006
    ..The findings of the proposed study will identify geographic disparities in survival and factors responsible, which can be used to develop and implement future interventions to reduce these disparities. [unreadable] [unreadable]..
  21. Folate-Genome Interactions in Colorectal Cancer
    PATRICK STOVER; Fiscal Year: 2007
    ..The long-term goal of this project is: (1). to determine the mechanism whereby alterations in folate metabolism influence cancer risk. ..
  22. CatheterScope for Intraluminal Image of Early.Neoplasia
    Eric Seibel; Fiscal Year: 2006
    ..abstract_text> ..
  23. Caregiver Coping Skills training for Lung Cancer
    Francis Keefe; Fiscal Year: 2006
    ..The proposed study rigorously evaluations methods for enhancing the effects of caregiver-assisted coping skills training in cancer patients and their caregivers. ..
  24. FUNCTION AND REGULATION OF GASTRIN
    Timothy Wang; Fiscal Year: 2008
    ..Overall, these studies will attempt to define the role of progastrin-derived peptides in stem cell regulation and in bridging genetic pathways in colorectal cancer. ..
  25. Phase II Clinical Trial Utilizing Lithium for Patients with Neuroendocrine Tumors
    Herbert Chen; Fiscal Year: 2008
    ..Besides surgery, there are limited curative and palliative treatments available to patients with metastatic NE tumors, emphasizing the need for development of other forms of therapy. [unreadable] [unreadable] [unreadable]..
  26. Sensitivity Mechanisms in Chromium Toxicity
    Anatoly Zhitkovich; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..
  27. Neighborhood effects on Quality of Life in Breast Cancer
    Mario Schootman; Fiscal Year: 2009
    ..g., individual and neighborhoods simultaneously) using a multi-pronged approach to improve QoL, as recently recommended by the Institute of Medicine. ..
  28. Surveillance for Hepatocellular Carcinoma among HCV-infected Veterans
    Hashem El Serag; Fiscal Year: 2009
    ..Evaluating the extent and patterns of HCC surveillance is crucial in understanding diffusion (and obstacles) of this practice and in designing interventions to improve the implementation of HCC surveillance. ..
  29. Regulating Neuroendocrine Phenotype in Cancer
    Herbert Chen; Fiscal Year: 2010
    ..Furthermore, these finding may permit development of components of raf-1 pathway as therapeutic targets in the treatment and palliation of NE tumors. ..
  30. Phase II Study of Imatinib Mesylate in Patients with Inoperable Melanoma
    Gary K Schwartz; Fiscal Year: 2010
    ..Dose reductions are allowed in the setting of toxicity. Imaging studies will be performed on an every 6 week schedule. ..
  31. Signaling Pathways in Medullary Thyroid Cancer
    Herbert Chen; Fiscal Year: 2004
    ..abstract_text> ..
  32. Gene Expression in Barrett's Esophagus
    Hashem El Serag; Fiscal Year: 2006
    ..We present preliminary data on microarray and RT-PCRanalyses on 5 patients with BE that suggest an overactive Wnt pathway: we have also assembled the essential components of a successful study using microarrays. ..
  33. Parenchymal/Stem Cell Pathways for Salivary Gland Repair
    Robert Redman; Fiscal Year: 2003
    ..abstract_text> ..
  34. TRANSGENIC MOUSE MODELS OF PANCREATIC EXOCRINE FUNCTION
    ROBERT DE LISLE; Fiscal Year: 2003
    ..That over expresses Muclin in the pancreatic acinar cell using the rat elastase promoter to direct cell specific expression. ..
  35. PATHOGENEISIS OF CYSTIC FIBROSIS IN THE GI SYSTEM
    ROBERT DE LISLE; Fiscal Year: 2003
    ..Pathology and Muclin expression will be compared in CF mice, and CF mice crossed with gastrin deficient mice (lack gastric acid secretion) to normalize intestinal Ph. ..
  36. Symposium on Cancer Metastasis and Lymphovascular System
    STANLEY LEONG; Fiscal Year: 2004
    ..abstract_text> ..
  37. ANXIETY, DEPRESSION, AND NONCARDIAC CHEST PAIN
    Francis Keefe; Fiscal Year: 2005
    ..This study may lead to major advances in our understanding of non-cardiac chest pain and enlarge our repertoire of methods for effectively treating non-cardiac chest pain. ..
  38. MENTORING FOR NEW CANCER THERAPEAUTICS
    Gary Schwartz; Fiscal Year: 2005
    ..This K24 award mechanism represents the essence of what we are proposing and for which support is needed. ..
  39. SPOUSE GUIDED PAIN MANAGEMENT TRAINING FOR CANCER PAIN
    Francis Keefe; Fiscal Year: 2002
    ..This study may lead to major advances in our understanding of cancer pain that occurs at end-of-life and enlarge our repertoire of methods for effectively treating this pain. ..
  40. Fine Needle Aspiration Biopsy(FNAB) Needle Device
    Vinod Shidham; Fiscal Year: 2002
    ..Apart from the worldwide market, the potential market in United States alone should exceed $1,500,000 per year. ..
  41. MOLECULAR MECHANISMS OF ANTIMICROTUBULE AGENTS
    Charles Coltman; Fiscal Year: 2001
    ..This study may lead to a better selection of patients for either combination therapy, leading to improved quality of care and clinical outcome. ..
  42. In Vivo Raman Spectroscopy of Barrett's Esophagus
    Louis Michel Wong Kee Song; Fiscal Year: 2005
    ..abstract_text> ..
  43. Failure of FasL Mediated Pathways in Tumor Angiogenesis
    Vijay Shah; Fiscal Year: 2006
    ..These insights may lead to novel and effective therapeutic strategies that target this pathway to prevent angiogenesis, and thereby prevent colorectal tumor development growth and spread. ..
  44. Novel Insights into Gastric Cancer
    Lopa Mishra; Fiscal Year: 2003
    ..The proposed workshop, entitled "Novel Insights into Gastric Cancer" will take place on October 3rd, 2003 at the Levy Center, Georgetown University, Washington, D.C. ..
  45. Noninvasive Monitoring Glutathione Metabolism in Tumors
    MICHAEL GAMCSIK; Fiscal Year: 2010
    ..abstract_text> ..
  46. Growth Factors, Curcumin and Colon Carcinogenesis
    Pomila Singh; Fiscal Year: 2010
    ..The results of these studies are expected to help in developing mechanism-based strategies for preventative/treatment protocols for CRCusing curcumin like agents. ..
  47. Spatial, Temporal, Social Disparities in Breast Cancer
    Mario Schootman; Fiscal Year: 2010
    ....
  48. Stem Cells and Gastric Cancer
    TIMOTHY CRAGIN WANG; Fiscal Year: 2010
    ....
  49. Curbing Tobacco Use in Suburban and Rural Schools
    Alexander V Prokhorov; Fiscal Year: 2010
    ..The study will be a group-randomized, controlled trial with 2000 participants aged 14-16 years from 16 high schools in suburban and rural southeast Texas. Follow-up assessments will be conducted at 6 weeks and at 6, 12, and 18 months. ..
  50. Experimentally Validated Mathematical Modeling of Oncolytic Virus Infection
    WOLFGANG KORN; Fiscal Year: 2009
    ..However, the results of these studies will be applicable to other types of cancer, thus potentially contribute to improving the treatment outcome for many cancer patients in the future. ..
  51. Process & Outcomes of BRCAL/2 clinical testing
    Judy Garber; Fiscal Year: 2003
    ..The information learned from this project may help to create a standard for the optimal conduct of BRCA 1/2 testing, and potentially for other predisposition testing as well. ..
  52. End of Life Communication Skills for Oncology Fellows
    Anthony Back; Fiscal Year: 2005
    ..This program will create a formal curriculum for communication skills that could be replicated in many institutions to improve the quality of oncologists-patient communication--and ultimately the quality of cancer care--nationwide. ..
  53. Healthcare Team Approach to Tobacco Cessation
    Alexander Prokhorov; Fiscal Year: 2005
    ..Also, to encourage and facilitate health care provider outreach in the community. AIM 5: To evaluate the proposed tobacco cessation counseling strategies for their costs and benefits. ..
  54. The Perception of Cancer Risk in Patients with Barrett's Esophagus
    Nicholas Shaheen; Fiscal Year: 2007
    ..The resultant study application will assess health-related quality of life, health-related anxiety and healthcare utilization as outcomes. [unreadable] [unreadable]..
  55. TRANSCRIPTIONAL CONTROL OF GASTRIN
    Juanita Merchant; Fiscal Year: 2007
    ..For type specifications, see instructions on page 6.) RESEARCH GRANT TABLE OF CONTENTS Page Numbers Face Page 1 Description, ..
  56. Molecular Mechanisms of Portal Hypertension
    Vijay Shah; Fiscal Year: 2007
    ..abstract_text> ..
  57. Phase I Trial of Safingol and Cisplatin
    Gary Schwartz; Fiscal Year: 2006
    ..conduct "proof of principle" biological assays to measure the degree of ceramide production and/or S1P inhibition, either of which may be predictive of clinical outcome or toxicity. ..
  58. Integral activity of the p53 family and its role in progression of colon tumors
    Alexander Zaika; Fiscal Year: 2008
    ..This information may provide new avenues for the development of novel prognostic and therapeutic targets. [unreadable] [unreadable] [unreadable]..
  59. FASEB Summer Conference: Folate, B12 and 1C Metabolism
    PATRICK STOVER; Fiscal Year: 2004
    ..Similarly, the poster sessions also highlight the activities and needs of the younger participants. ..
  60. TGF-BETA REGULATION OF INTESTINAL EPITHELIAL CELLS
    John Barnard; Fiscal Year: 2009
    ..abstract_text> ..
  61. 14th International Symposium on Regulatory Peptides
    Timothy Wang; Fiscal Year: 2002
    ..abstract_text> ..
  62. Capturing cancer cells with peptide bead technology
    Derick Lau; Fiscal Year: 2003
    ..The development of this technology will greatly enhance our ability of diagnosing malignant pleural effusion, and it will provide a model for capturing and expanding exfoliated malignant cells in other body fluids. ..
  63. THE ROLE OF MYCOBACTERIA IN CROHN'S DISEASE
    David Graham; Fiscal Year: 2005
    ..The results of this study should either confirm or refute the proposed etiologic association of M. paratuberculosis and Crohn's disease as well as the identification of patients with Crohn's disease and M. paratuberculosis. ..
  64. BREAST CANCER SYMPOSIUM
    Charles Coltman; Fiscal Year: 2003
    ..Abstracts accepted for presentation are published in the journal Breast Cancer Research and Treatment. All symposia to date have been granted Category 1, AMA credit for continuing education. ..